^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Adenocarcinoma

    Related cancers:
    4d
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    7d
    NRG-GY031: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    7d
    NRG-GY025: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=81, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Jul 2032 | Trial primary completion date: Apr 2026 --> Jul 2032
    Trial completion date • Trial primary completion date • Mismatch repair • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    8d
    Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Jun 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Triapine (3-AP)
    10d
    D-salicin induces oxidative stress-mediated ERK1/2 suppression and apoptosis in endometrial cancer cells. (PubMed, Oncol Lett)
    Elevated oxidative burden was associated with caspase-3 activation and concentration-dependent suppression of ERK1/2 phosphorylation, both of which were attenuated by N-acetylcysteine (NAC) co-treatment...Notably, NAC co-treatment partly restored p-ERK1/2 levels under the IC50 condition (P<0.01 vs. D-salicin alone), supporting a redox-linked contribution to ERK pathway modulation. Collectively, these findings indicated that D-salicin exerts selective anticancer effects in endometrial cancer cells by inducing oxidative stress and disrupting ERK1/2-mediated survival signaling, with NAC-sensitive modulation consistent with involvement of a redox-responsive ROS-ERK axis.
    Journal
    |
    CASP3 (Caspase 3)
    22d
    Relationship Between Systemic Inflammatory Markers and Histopathological Parameters in Endometrial Adenocarcinoma. (PubMed, J Clin Med)
    Their association with survival outcomes and local tumor extension highlights their potential clinical value in preoperative risk stratification and individualized treatment planning. Future prospective studies integrating these markers with molecular classification data are required.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • CRP (C-reactive protein)
    28d
    Primary endometrial squamous cell carcinoma with molecular Characterization: A case report. (PubMed, Gynecol Oncol Rep)
    Current evidence suggests that PESCC may exhibit molecular and immunophenotypic features that differ from conventional endometrial adenocarcinoma; however, available data remain sparse. Further accumulation of molecularly characterized cases is necessary to clarify its biological behavior and staging implications.
    Journal
    |
    TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon)
    |
    TP53 mutation • POLE mutation
    1m
    V-COSMOS: Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy (clinicaltrials.gov)
    P=N/A, N=160, Not yet recruiting, Cukurova University
    New trial
    1m
    Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus. (PubMed, Gynecol Oncol Rep)
    Post-operatively, she received six cycles of carboplatin, paclitaxel, and dostarlimab every three weeks, followed by maintenance dostarlimab. This case illustrates that aggressive multimodal therapy including immune checkpoint inhibition may achieve durable disease control in advanced-stage MMR-deficient uterine LCNEC. While the relative contributions of surgery, chemotherapy, radiation, and immunotherapy cannot be separated, the favorable outcome supports further investigation of immunotherapy in rare high-grade endometrial neuroendocrine carcinomas and underscores the importance of including these histologies in clinical trials.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FOLR1 ( Folate receptor alpha ) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    HER-2 negative • TP53 wild-type • PD-L1 negative
    |
    carboplatin • paclitaxel • Jemperli (dostarlimab-gxly)
    1m
    ACR-368-201: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (clinicaltrials.gov)
    P2, N=401, Recruiting, Acrivon Therapeutics | Trial completion date: Apr 2027 --> Nov 2027 | Trial primary completion date: Oct 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    gemcitabine • prexasertib (ACR-368)
    2ms
    PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028
    Trial completion date
    2ms
    ACR-368-201: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (clinicaltrials.gov)
    P2, N=353, Recruiting, Acrivon Therapeutics | N=72 --> 353
    Enrollment change
    |
    gemcitabine • prexasertib (ACR-368)